Clinical Research Center
We have a 4-bed Phase I Center at Yeditepe University Koşuyolu Hospital and a 24-bed Bioequivalence Center at Acıbadem. These centers conduct Phase I clinical trials as well as bioavailability/bioequivalence studies.
Our Clinical Center operates in accordance with Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards, and provides services approved by the Ministry of Health.
Our aim is to conduct international studies in our country, contribute to our national goals, and position Turkey among the leading countries in clinical trials.
Yeditepe University Phase 1 Clinical Research Center
Yeditepe University Phase 1 Clinical Research Center is an important research center that assists in the development of new treatment methods and medications. Our center is equipped with modern infrastructure and technological equipment necessary for clinical research. Yeditepe University Phase 1 Clinical Research Center meets all the infrastructure requirements such as patient beds, examination rooms, laboratories, and pharmacies, ensuring that research is conducted to the highest standards. In addition, the fact that we have the infrastructure and experience to conduct Phase 2 and Phase 3 clinical trials in our center further increases the scope and effectiveness of our research.
Yeditepe University Phase 1 Clinical Research Center contributes to the development of not only traditional treatment methods but also innovative treatment options. It also conducts medical device studies and contributes to the developments in health technologies through research in this field. Thanks to collaborations with world- renowned biotechnology companies and research centers, treatment options that follow the latest developments are offered to our patients in Turkey. These strategic collaborations both improve the quality of our clinical research and contribute to advances in healthcare.
Yeditepe University Phase 1 Clinical Research Center plays an important role in the field of clinical research and contributes to advances in health sciences. As a leading center for the testing and safe application of innovative treatment options, Yeditepe University is making a major impact in the field of healthcare by offering the latest treatment methods to our patients in Turkey and neighboring countries.
For more information about our clinic, you can contact our responsible team. You can reach us at yu-agam@yeditepe.edu.tr or by calling 0 216 428 31 66, Extension: 187 – 0537 975 8268.
| Sponsorship | Protocol Code | Research Title | Principal Investigator | Phase |
|---|---|---|---|---|
| BioNeTech SE | BNT116-01 | LuCA-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Prof. Dr. Başak Oven | Phase 1 |
| BioMarin Pharmaceutical Inc. | BMN 351-201 | A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants with Duchenne Muscular Dystrophy | Prof. Dr. Haluk Aydin Topaloğlu | Phase 1 |
| Samsung Bioepis Co., Ltd. | SB27-1005 | A Phase I, Randomised, Double-blind, Three-arm, Parallel Group, Multicentre Study to Compare the Pharmacokinetics (PK), Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, European Union) [EU] Sourced Keytruda and the United States of America (USA) Sourced Keytruda in Subjects with Stage IIIA Non-small Cell Lung Cancer Following Complete Resection and Adjuvant Platinum-based Chemotherapy | Prof. Dr. Başak Oven | Phase 1 |
| BioNeTech SE | BNT327-02 | A Phase II, Multi-site, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination with Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer | Prof. Dr. Başak Oven | Phase 2 |
| BioNeTech SE | BNT327-01 | A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-Stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer | Prof. Dr. Serkan Çelik | Phase 2 |
| Regeneron Pharmaceuticals, Inc. | R2810-ONC-2045 | A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With Fianlimab (Anti-LAG-3 Antibody) in Monotherapy in First-line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% | Prof. Dr. Başak Oven | Phase 2 |
